David Hutton


Results unveiled from phase 2/3 gene therapy study for XLRP

While Biogen’s XIRIUS study did not meet its primary endpoint of demonstrating a statistically significant improvement in treated eyes, positive trends were observed across several clinically relevant prespecified secondary endpoints.

Minimally invasive retinal reattachment procedure leads to enhanced photoreceptor integrity

A study led by investigators at St. Michael's Hospital of Unity Health Toronto supports pneumatic retinopexy as a primary retinal reattachment technique to achieve better long-term integrity of photoreceptors.

Enrollment completed in VEGA-1 Phase 2 clinical trial for presbyopia treatment

Ocuphire Pharma has completed enrollment in the VEGA-1 Phase 2 clinical trial evaluating the safety and efficacy of drops to treat presbyopia.

Investigators develop technique to assess progression of sickle cell retinopathy

May 11, 2021

Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss.